LTX-109 (3%)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for LTX-109 (3%), covering 2023-06-05 to 2023-06-05. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus [Phase 2]